ECSP088296A - Compuestos terapéuticos - Google Patents

Compuestos terapéuticos

Info

Publication number
ECSP088296A
ECSP088296A EC2008008296A ECSP088296A ECSP088296A EC SP088296 A ECSP088296 A EC SP088296A EC 2008008296 A EC2008008296 A EC 2008008296A EC SP088296 A ECSP088296 A EC SP088296A EC SP088296 A ECSP088296 A EC SP088296A
Authority
EC
Ecuador
Prior art keywords
therapeutic compounds
methods
solvate
formula
preparation
Prior art date
Application number
EC2008008296A
Other languages
English (en)
Inventor
Mitchell David Nambu
John Howard Tatlock
Brian Douglas Paterson
Sylvie Kim Sakata
Leena Bharat Kumar Patel
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP088296A publication Critical patent/ECSP088296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMENLa presente invención proporciona compuestos de fórmula (I), o una de sus sales o solvatos farmacéuticamente aceptables, métodos para su preparación, métodos para su uso y formulaciones farmacéuticas que los comprenden.
EC2008008296A 2005-09-23 2008-03-19 Compuestos terapéuticos ECSP088296A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72015105P 2005-09-23 2005-09-23
US72311505P 2005-10-03 2005-10-03
US72546905P 2005-10-11 2005-10-11
US76225606P 2006-01-25 2006-01-25
US82166406P 2006-08-07 2006-08-07

Publications (1)

Publication Number Publication Date
ECSP088296A true ECSP088296A (es) 2008-06-30

Family

ID=37889174

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008296A ECSP088296A (es) 2005-09-23 2008-03-19 Compuestos terapéuticos

Country Status (28)

Country Link
US (1) US7868026B2 (es)
EP (1) EP1937639B1 (es)
JP (1) JP4336738B2 (es)
KR (1) KR100975448B1 (es)
CN (1) CN101287708B (es)
AT (1) ATE459603T1 (es)
AU (1) AU2006293605B2 (es)
BR (1) BRPI0616156A2 (es)
CA (1) CA2621805C (es)
CY (1) CY1110010T1 (es)
DE (1) DE602006012713D1 (es)
DK (1) DK1937639T3 (es)
EA (1) EA014329B1 (es)
EC (1) ECSP088296A (es)
ES (1) ES2340200T3 (es)
GE (1) GEP20115230B (es)
HR (1) HRP20100272T2 (es)
IL (1) IL189666A (es)
MA (1) MA29791B1 (es)
MY (1) MY143391A (es)
NO (1) NO20081844L (es)
NZ (1) NZ566136A (es)
PL (1) PL1937639T3 (es)
PT (1) PT1937639E (es)
RS (2) RS20080118A (es)
SI (1) SI1937639T1 (es)
TN (1) TNSN08139A1 (es)
WO (1) WO2007034312A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511812A (zh) * 2006-07-05 2009-08-19 辉瑞产品公司 作为细胞色素p450抑制剂的吡唑衍生物
WO2008088540A2 (en) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN101815512B (zh) * 2007-10-04 2013-04-24 弗·哈夫曼-拉罗切有限公司 环丙基芳基酰胺衍生物和其用途
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
EP2349279A4 (en) * 2008-10-28 2013-12-25 Univ Leland Stanford Junior MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
EA020460B1 (ru) 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
EP2424517A4 (en) * 2009-05-01 2013-01-23 Raqualia Pharma Inc SULFAMOYLBENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
SI3122750T1 (sl) 2014-03-26 2019-12-31 F. Hoffmann-La Roche Ag Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
WO2016101118A1 (en) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Amidoethyl azole orexin receptor antagonists
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フェノキシメチル誘導体
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN116903531B (zh) * 2023-07-21 2025-12-12 上海中医药大学 细胞色素p450酶3a4的抑制剂及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers

Also Published As

Publication number Publication date
CN101287708A (zh) 2008-10-15
MA29791B1 (fr) 2008-09-01
HRP20100272T1 (en) 2010-06-30
CA2621805C (en) 2011-05-10
HRP20100272T2 (hr) 2010-07-31
SI1937639T1 (sl) 2010-07-30
KR20080038431A (ko) 2008-05-06
PT1937639E (pt) 2010-04-23
JP2009508931A (ja) 2009-03-05
US20070167497A1 (en) 2007-07-19
CY1110010T1 (el) 2015-01-14
AU2006293605A1 (en) 2007-03-29
EA014329B1 (ru) 2010-10-29
ES2340200T3 (es) 2010-05-31
KR100975448B1 (ko) 2010-08-11
WO2007034312A3 (en) 2007-08-23
TNSN08139A1 (fr) 2009-07-14
US7868026B2 (en) 2011-01-11
CA2621805A1 (en) 2007-03-29
EA200800542A1 (ru) 2008-08-29
DE602006012713D1 (de) 2010-04-15
EP1937639B1 (en) 2010-03-03
IL189666A0 (en) 2008-08-07
ATE459603T1 (de) 2010-03-15
PL1937639T3 (pl) 2010-07-30
GEP20115230B (en) 2011-06-10
NO20081844L (no) 2008-05-29
EP1937639A2 (en) 2008-07-02
JP4336738B2 (ja) 2009-09-30
RS51349B (sr) 2011-02-28
HK1120506A1 (en) 2009-04-03
IL189666A (en) 2011-12-29
BRPI0616156A2 (pt) 2011-06-07
AU2006293605B2 (en) 2011-05-19
WO2007034312A2 (en) 2007-03-29
NZ566136A (en) 2010-04-30
RS20080118A (sr) 2009-05-06
CN101287708B (zh) 2012-02-29
DK1937639T3 (da) 2010-05-10
MY143391A (en) 2011-05-13

Similar Documents

Publication Publication Date Title
ECSP088296A (es) Compuestos terapéuticos
UY30460A1 (es) Compuestos terapéuticos
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
CR11106A (es) Inhibidores de cinasa p710 s6
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
DOP2010000387A (es) Compuestos pirazolicos 436
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
UY32203A (es) Amino pirimidinas y su uso en terapia
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY28342A1 (es) Nuevos compuestos
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CR11333A (es) cis-IMIDAZOLINAS QUIRALES
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
ECSP109934A (es) Compuesto - 946
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
CO6270311A2 (es) Derivados bis-(sulfonilamino) en terapia 066
GT200500307A (es) Compuestos quimicos
CR9954A (es) Derivados de pirazina
UY30736A1 (es) Compuestos quimicos 537
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
UY29875A1 (es) Compuestos quimicos